AB Science annonce des résultats de phase 2B/3 positifs du masitinib dans les formes progressives de la sclérose en plaques
February 20, 2020 13:39 ET
|
AB Science
Paris, 20 février 2020, 19h30 AB Science annonce des résultats de phase 2B/3 positifs du masitinibdans les formes progressives de la sclérose en plaques Le masitinib...
AB Science announces positive top-line Phase 2B/3 results for oral masitinib in progressive forms of multiple sclerosis
February 20, 2020 13:39 ET
|
AB Science
Paris, February 20, 2020, 7.30pm AB Science announces positive top-line Phase 2B/3 results for oral masitinib in progressive forms of multiple sclerosis Masitinib significantly delays...
Global Auto Injectors Market is Expected to Reach USD 172.38 Billion by 2025 : Fior Markets
January 27, 2020 07:00 ET
|
Fior Markets
Newark, NJ, Jan. 27, 2020 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, the global auto injectors market is expected to grow from USD 27.82 Billion in 2017 to USD 172.38 Billion...
Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate)
November 22, 2019 07:30 ET
|
Biogen Inc.
CAMBRIDGE, Mass., Nov. 22, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced detailed results from the Phase 3 EVOLVE-MS-2 study demonstrating the improved patient-assessed...
Interferon Beta Treatments, Including PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a), Receive Positive CHMP Opinion for Use During Pregnancy and Breastfeeding
September 23, 2019 03:00 ET
|
Biogen Inc.
Positive opinion is supported by data from more than 1,000 real-world pregnancy outcomes Data indicate no increased risk of major congenital anomalies after exposure to interferon beta before...
New Research Demonstrate Biogen’s Continued Commitment to Improve Care of Patients with Multiple Sclerosis Across Treatment Spectrum
September 12, 2019 05:00 ET
|
Biogen Inc.
Data highlight benefits of TYSABRI® (natalizumab) treatment in early multiple sclerosis for achieving NEDA (no evidence of disease activity) and improving disability and cognitionAn analysis of data...
New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA® (dimethyl fumarate) Over 10 Years
September 11, 2019 05:00 ET
|
Biogen Inc.
TECFIDERA consistently maintained low levels of disease activity with no increased risk in adverse events over a decade of treatmentLatest interim data from Phase 3 EVOLVE-MS-1 trial show Biogen and...
Fluidigm Launches Imaging Mass Cytometry Immuno-Oncology Panel Kits and Advanced CyTOF Software at the 2019 World Molecular Imaging Congress (WMIC)
September 04, 2019 08:30 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), the global leader in highly multiplexed single-scan tissue imaging, today announced the launch of...
Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis
July 30, 2019 07:30 ET
|
Biogen Inc.
— Diroximel Fumarate Demonstrated Statistically Superior Gastrointestinal (GI) Tolerability on EVOLVE-MS-2 Study’s Primary Endpoint Assessing Self-Reported GI Events — — Discontinuations Due to GI...
EU Licensed European Pharmaceutical Company, Freia Farmaceutici Srl NEWSFLASH
July 22, 2019 10:51 ET
|
LGC Capital LTD.
MONTRÉAL, July 22, 2019 (GLOBE NEWSWIRE) -- LGC Capital Ltd. (TSXV: LG and OTC-QB: LGGCF) (“LGC”) is pleased to announce that it has paid the 2nd Tranche, as contractually agreed, in acquiring...